In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

Over the past decade there have been significant advances in the molecular
characterization of colorectal cancer (CRC) that are driving treatment decisions. Expanded …

Colorectal cancer (CRC) is a significant cause of cancer-related morbidity and mortality all
over the world. Improvements of cytotoxic and biologic agents have prolonged the survival in …

Highlights•The epidermal growth factor (EGFR) is a therapeutic option for patients with all
RAS WT metastatic colorectal cancer (mCRC).•A better knowledge of the mechanism of …

Between 8% and 12% of patients with metastatic colorectal cancer (mCRC) harbor a BRAF-
V600E mutation in their tumors, which is associated with a poor response to standard …

Despite significant progress in management of metastatic colorectal cancer (mCRC)
pertaining to better screening procedures and amelioration of the therapeutic …

Importance Rechallenge therapy with anti–epidermal growth factor receptor (EGFR) drugs
has been suggested in patients with chemo-refractoryRASwild-type (WT) metastatic …

Background. Survival of patients with metastatic colorectal cancer (mCRC) has been
significantly improved with the introduction of the monoclonal antibodies targeting the …

Simple Summary The BRAFV600E mutation accounts for 8–10% of metastatic colorectal
cancer (mCRC) patients and it is an established prognostic factor. Median overall survival of …

In the last two decades, great efforts have been made in the treatment of metastatic
colorectal cancer (mCRC) due to the approval of new target agents for cytotoxic drugs …